The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Science and Technology Council, Taiwan
Age
20–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed SARS-CoV-2 infection by PCR, documented positive test, or clinician diagnosis
Meeting CDC criteria for Post-COVID Conditions (Long COVID) as the presence of new, returning, or ongoing symptoms ≥4 weeks after confirmed SARS-CoV-2 infection
Hamilton Depression Rating Scale (HAMD-21) score ≥18 at baseline
Stable antidepressant treatment for ≥4 weeks or no current antidepressant use; and
Ability to provide written informed consent
You may not be if
Current or past six-month diagnosis of psychotic disorder, bipolar disorder, substance use disorder, or other major psychiatric conditions based on ICD-10 or DSM-5 criteria
Significant neurological or medical comorbidities (eg, epilepsy, traumatic brain injury, autoimmune disease, cancer), acute infections, or clinically significant laboratory abnormalities
Regular use of SPM or EPA supplementation \>0·5 g/day
Known allergy or intolerance to omega-3 fatty acids or SPMs; and
Requirement for inpatient psychiatric care due to acute suicide risk
Clareo Health | The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms
